Fantastic overview on how to image the tricuspid valve - extremely useful for interventional cardiologists as well! @chrismeduri @GilbertTangMD @nickaram #TreatTR

Just back from a session on AI and publishing. I learned far more than I could teach about a topic that often makes me feel overwhelmed, and whose alpha and omega I still struggle to grasp. A few talks on AI being used well actually opened my eyes a little.

In between something that’s been happening at the Journal lately, and I think it says a lot about where we are. We’re starting to receive more Letters to the Editor than ever before, often from the same authors. Someone might say: great, it means the journal is generating debate. Well, not quite. These letters are often flat, have very little to say, and sometimes seem designed simply to highlight a minor point of a paper rather than raise a genuinely critical aspect. Not particularly interesting, in other words.

So, reject? Yes. But today my eye caught something in the AI statement included in the cover letter, which we now require as part of our policy: “OpenAI ChatGPT assisted with literature checking, scientific framing, manuscript drafting and language editing. Both authors have reviewed and approved the final text and accept full responsibility for its content.” I mean, seriously: what exactly did the humans do here, if AI did pretty much everything except put their names on the paper?

As I said during the session, I don’t want to sound like a dinosaur. I actually like AI, and I use it myself. But this scenario (an AI-generated letter signed off by a human) is one aspect of the publish-or-perish culture that I really cannot get behind. #TCT2026

Hot of the press 🔥 - a clinical consensus statement of #EAPCI_ESC and #ACVC_ESC on temporary #MCS in #CardShock just published in #EHJ
Tremendously important and excellent collaborative work 👏
@ehj_ed @escardio @ESC_Journals

@alaide_chief @EHJACVCEiC @sighalvo @CHassager Kunadian @thiele_holger @CVandenbriele

doi.org/10.1093/eurhea…

Great to see this work Becky and Pepe also pushing the volumetric-corrected metrics by CMR in TR evaluation. It confirms the role of RV-PAC: tinyurl.com/59pt6y7m. Wouldn’t be wonderful that we can one day use this more widely for our patients?! @FabienPraz @sarano_maurice

The European Heart Journal - Cardiovascular Interventions, the newest addition to the ESC Journal Family, and the official journal of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) is looking for its first Editor-in-Chief!

We invite applications s with a proven ability to build strong scientific partnerships.

Apply by Tuesday, 20 October 👉 ow.ly/N2ja50ZVgwq

#EAPCI #EHJInterventions @EAPCIPresident

⭐️Submit your Clinical Cases
⭐️ Submit your Innovations& Technology #AI #digital #newtechnologies

#EAPCI27 Congress Milan 18-20 February

@EAPCIPresident @escardio

🤔 When do signals become evidence? This editorial discusses the evolving evidence on #TTVR, hard clinical endpoints, and the challenge of identifying the right patient for transcatheter tricuspid interventions. Read more ⬇️
onlinecjc.ca/article/S0828-…
#CJC

Acute management of periprocedural stroke following TAVR. Should 24/7 on-site neurointerventional capabilities be a requirement for Heart Valve Centers? #JACCINT authors.elsevier.com/sd/article/S19…

Final opportunity to bring your science to #EAPCI27

The preliminary Scientific Programme is now live. Hear what awaits from Prof. Alaide Chieffo and Prof. @FabienPraz, then submit: escardio.org/events/congres…

Abstracts: extended to 29 September
Tech & Innovation: 1 October
Cli
#EAPCI @EAPCIPresident

Don’t miss the opportunity !
#EAPCI @escardio @EAPCIPresident

In this subanalysis of the SUMMIT study, conducted during our 2023 Everest expedition, we found a progressive increase in ventricular ectopic activity with increasing altitude. #JACCAdvances authors.elsevier.com/sd/article/S27…

Registration for the EAPCI Congress is officially open 🎟️🎉

As we evolve from last year's EAPCI Summit to a full Congress format, please note that a very affordable registration fee applies this year to help us deliver an even more comprehensive and impactful experience!

We ny of you can join us as possible, so there are several great ways to participate: 
✨ Register Early and take advantage of our early bird rates
✨ Become an EAPCI Member to have discounted fee 
✨ Reduced fees for young, NAP and low/lower-middle income countries 
✨ We are offering FREE registration and travel grants to support the authors of the 250 best abstract/clinical cases

Don't miss out on the opportunity to connect, learn, and shape the future of interventional cardiology.
Secure your spot today: lnkd.in/egiqXZuy

#EAPCIfamily #EAPCIcommunity #EAPCI27
@escardio

Registration for #EAPCI27 is open!

Step into simulations, learn through live cases, challenge clinical decisions in expert debate and exchange perspectives across the full Heart Team.

Register by 17 December to save the most bit.ly/3SNDxL7

The deadline for the the EAPCI 2027 Call for Technology & Innovation is fast approaching 🚨

We are looking for pioneering solutions that will transform cardiovascular interventions including:

⚙️ Novel devices & technologies
🤖 AI, digital health & robotics
🔬 Advanced imaging
📚 Next-gen els

There is still time to showcase your innovation on the European stage 🫀

⏳ Deadline: 1 October 2026
🔗 Submit your innovation today: escardio.org/events/congres…

#EAPCIinnovation #EAPCI27 #EAPCIcommunity
@escardio

@EAPCIPresident @alaide_chief @FabienPraz @GGStefanini @nickaram @valeriaparadies @a_sorropago @KardiologieHH @marioiancardio @IlkeCelikkale @aleks_gasecka Speaking about the joy of meeting friends @ESC

The EAPCI General Assembly in Munich during #ESCcongress has officially opened an exciting new chapter for our Association 💫 It was thrilling to see a completely full room as we reflected on the immense work accomplished over the last mandate!

We are incredibly proud that EAPCI with the other ESC associations 🌍 A heartfelt thank you goes out to all EAPCI pillars, chairs and committee members. The tremendous effort and enthusiasm you have poured into this community have driven our unprecedented growth. Thanks to your dedication we now proudly feature our own congress, a comprehensive educational pathway and soon our very own journal 📚

We express our sincere gratitude to outgoing President Prof Chieffo for her visionary leadership and we celebrate her on receiving the ESC Silver Medal🏅

Looking ahead, we are deeply inspired by the vision shared by incoming President Prof. Praz💡 His leadership promises seamless continuity and dynamic growth of our community in the years to come📈

Congratulations to our newly elected executive board! We anticipate a highly fruitful 2026–2028 mandate as we work together to advance the future of our Association 🫀

#EAPCIfamily #EAPCIcommunity #ESCCongress
@escardio

What a remarkable few days for EAPCI at #ESCCongress! ✨ From sharing scientific breakthroughs to the simple joy of reconnecting with old friends and colleagues, the atmosphere was truly special 🔬🤝🌍

The energy and presence at our General Assembly was outstanding, a heartfelt ho participated as our newly elected board outlined their vision for the mandate ahead 🚀

We’ll take these vibes straight into our next chapter ➡️ we can't wait to see you all at #EAPCI27 Congress in Milan this February 🇮🇹📅

#EAPCIfamily #EAPCIcommunity #ESCCongress
@escardio

Original Article: Tricuspid-Valve Intervention in Heart Failure (TRIC-I-HF trial) nej.md/4ilZJGr

#ESCCongress | @escardio

The 10 trials I am most looking forward to at the ESC Hot Lines next week (in no particular order):

LIBREXIA-ACS, where milvexian could end up like apixaban in APPRAISE-2, perhaps with less bleeding. Rivaroxaban did not exactly have an easy story after ATLAS ACS 2 either, sults. Although we know the trial was stopped for futility, the data remain important in the rollercoaster of FXI inhibitor trials.

EPIDAURUS, because I will be the Discussant in Hot Line 3. It compares ticagrelor or prasugrel with clopidogrel in patients with atrial fibrillation and acute coronary syndrome. So I know everything about it, but I am not telling you.

SWITCH-SWEDEHEART, because if this trial is positive for prasugrel, this might finally be the moment when I call back all my patients on ticagrelor and switch them one by one. If not, we can say we have been joking all along and that ISAR-REACT 5 was just an episode.

PREMIUM, because after NEOMINDSET and STOPDAPT-3, a third negative trial for an aspirin-free strategy (meaning P2Y12 inhibitor monotherapy from the outset) would probably put this rather radical idea to rest, making it indefensible.

ISOLEDS, comparing OCT- versus IVUS-guided PCI in distal left main disease. After OPTIMAL and IVUS-CHIP, which we are still recovering from, we really need something that leaves angiography out of the comparison.

TAVI-PCI, because I don’t know about you, but after NOTION-3 and PRO-TAVI, I am still somewhat confused.

POPular-ACE, one of my favourites because it addresses a simple question with a potentially clear answer that we could implement in the cath lab the very next day: do we actually need protamine after TAVI or not?

AIR-STEMI, continuing the elemental saga of the Ferrara group (the same investigators behind FIRE) this time using angio-derived FFR to identify non-culprit lesions in STEMI. There is some confusion here too, given that FLOWER-MI was negative while FRAME-AMI was positive.

A-CLOSE, evaluating chronic clopidogrel monotherapy and continuing the story started by HOST-EXAM and SMART-CHOICE 3 against aspirin, while resembling OPT-BIRISK in its comparison with DAPT.

PRAGUE-26, which deserves a special mention because I really like the idea of tackling a complicated problem with an extremely simple and inexpensive approach. The results could surprise us and tell us that the solution has been sitting right there all along: alteplase directly instilled into the pulmonary arteries—a strategy we practically never use, and perhaps we are wrong not to.

In preparation for #ESCCongress 2026 🇩🇪 the EAPCI Congress and Young Committees have curated a special selection of scientific sessions just for you 🧳🛫

Get ready to learn the latest research, clinical updates and breakthroughs in #InterventionalCardiology

Don't miss this global leaders, engage in high-level discussions, and elevate your clinical practice 🩺🫀

Download the official App and start browsing the Programme

App Store: apps.apple.com/it/app/esc-con…
Google Store: play.google.com/store/apps/det…

@escardio
#EAPCIfamily #EAPCIcommunity #ESCCongress

2hr CSI Webinar tomorrow on Tricuspid Regurgitation! FREE! us02web.zoom.us/webinar/regist… @ACCinTouch @escardio